Skip to Content
Merck
  • The evaluation of nasal mupirocin to prevent Staphylococcus aureus burn wound colonization in routine clinical practice.

The evaluation of nasal mupirocin to prevent Staphylococcus aureus burn wound colonization in routine clinical practice.

Burns : journal of the International Society for Burn Injuries (2014-04-02)
M E H Jaspers, R S Breederveld, W E Tuinebreijer, B M W Diederen
ABSTRACT

Staphylococcus aureus wound colonization frequently occurs in patients with burns and can cause impaired wound healing. Nasal mupirocin application may contribute to the reduction of burn wound colonization of endogenous origin, whereas colonization by the exogenous route can be reduced by blocking cross-infection from other sources. In this study we evaluated whether the implementation of routine treatment of patients and burn center personnel using nasal mupirocin ointment reduces S. aureus burn wound colonization. We composed three study groups, consisting of a control period (Control), a mupirocin period (MUP), in which patients with burns were all receiving nasal mupirocin at admission, and a mupirocin+personnel period (MUP+P), in which we also screened the burn center personnel and decolonized S. aureus carriers by nasal mupirocin. The patients who carried S. aureus in their nose and did not have S. aureus burn wound colonization at admission were considered as patients susceptible for the use of nasal mupirocin. In these patients, the S. aureus burn wound colonization rate was the same in all study groups. S. aureus nasal carriage was a significant independent risk factor for burn wound colonization (OR: 3.3; 95% CI: 1.4-7.6) when analyzed within the three study groups. Although S. aureus carriage is a significant risk factor for developing burn wound colonization, the routine use of nasal mupirocin did not contribute to a reduction of burn wound colonization.

MATERIALS
Product Number
Brand
Product Description

USP
Mupirocin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Mupirocin, ≥92% (HPLC), powder